# 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

> **NCT00132015** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 37 (estimated)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Nonneoplastic Condition
- Precancerous Condition

## Interventions

- **DRUG:** tanespimycin

## Key facts

- **NCT ID:** NCT00132015
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-12
- **Final completion:** 2008-06
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132015, "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00132015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*